La catena delle opzioni mostra i dati chiave delle opzioni azionarie di K92 Mining a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per K92 Mining..

K92 Mining (OTC:KNTNF) Azioni, Catena delle Opzioni

K92 Mining Inc is engaged in the exploration, development, and mining of mineral deposits near the mine, including Blue Lake, in Papua New Guinea.

K92 Mining Inc

OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) reported quarterly losses of $(1.17) per share. This is a 178.57 percent decrease over losses of $(0.42) per share from the same period last year. The company reported $5.78 million in sales this quarter. This is a 0.46 percent decrease over sales of $5.81 million the same period last year.

Earnings

News

OceanPal Q4 EPS $(1.17) Down From $(0.42) YoY, Sales $5.78M Down From $5.81M YoY

Apollo CEO Marc Rowan Says I Expect Over The Next 90 Days We'll See The Beginnings Of Countries Coming To Make Deals

SNDL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) ("SNDL") and 1CM Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/EPIC#CSE">EPIC</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/MILFF#OTCQB">MILFF</a>) (FSE: IQ70) ("1CM") are&nbsp;pleased to announce that they have&nbsp;entered into an arrangement&nbsp;agreement (the "Agreement") pursuant to which SNDL will acquire 32&nbsp;cannabis retail stores&nbsp;(the "Transaction")&nbsp;operating under the Cost Cannabis and T Cannabis banners in Ontario, Alberta and Saskatchewan (the "1CM Stores"). Unless otherwise specified herein, all amounts are in Canadian currency.
Under&nbsp;the terms of&nbsp;the Agreement, SNDL will acquire, with the option to assign, the 1CM Stores for total consideration (the "Purchase Price") of $32.2&nbsp;million in cash, subject to certain adjustments at the closing of the Transaction (the "Closing").&nbsp;The 1CM Stores are comprised of 2&nbsp;stores in Alberta, 3 stores&nbsp;in Saskatchewan and 27&nbsp;stores located in Ontario. The&nbsp;1CM&nbsp;Stores&nbsp;generated annual revenue of an aggregate&nbsp;of $53 million&nbsp;the fiscal year ended August 31, 2024 with 30 active stores at the fiscal year end.&nbsp;The acquisition of the 1CM Stores will bring SNDL's&nbsp;total owned and franchised cannabis retail store count to 219.

CSE:EPIC

MILFF

SNDL

SNDL Inc. To Acquire 32 Cannabis Retail Stores Operating Under Cost Cannabis And T Cannabis Banners In Ontario, Alberta, And Saskatchewan From 1CM Inc. For $32.2M, Increasing SNDL's Total Retail Store Count To 219

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and maintains $60 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target

Citigroup analyst Ryan Levine upgrades Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) from Neutral to Buy and lowers the price target from $334 to $232.

Upgrades

Citigroup Upgrades Constellation Energy to Buy, Lowers Price Target to $232

Electronics manufacturer Foxconn Technology Co <a href="https://www.benzinga.com/topic/japan" target="_blank" rel="noreferrer noopener">is eyeing Japanese</a> automakers, including Nissan Motor Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANF#OTC">NSANF</a>), to form a Japan-Taiwan alliance.
According <a href="https://asia.nikkei.com/Editor-s-Picks/Interview/Taiwan-s-Foxconn-hopes-to-work-with-Nissan-others-on-EV-production" target="_blank" rel="noreferrer noopener">to</a> Nikkei Asia, Foxconn EV chief strategy officer Jun Seki revealed the agreement during a <a href="https://www.benzinga.com/markets/asia/25/03/44508263/apple-and-nvidia-supplier-foxconn-to-present-ev-plans-at-japan-seminar-following-mitsubishi-deal-report" target="_blank" rel="noreferrer noopener">Tokyo seminar on</a> Tuesday.
Foxconn, also known as Hon Hai Precision (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNHAY#OTC">HNHAY</a>), is currently competing with Chinese brands focused on battery-powered vehicles, looking to win market share in Europe, Brazil, and Thailand.
Foxconn, an Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) supplier, plans to launch an electric bus and a battery-powered microbus in Japan in 2027, Reuters cited Seki.
Also Read: <a href="https://www.benzinga.com/25/04/44631510/asml-to-boost-japan-workforce-5x-amid-global-race-for-advanced-semiconductor-tech" target="_blank" rel="noreferrer noopener">Chip Equipment Maker ASML To Boost Japan Workforce 5x Amid Global Race For Advanced Semiconductor Tech</a>
It focuses on providing business-to-business services with EV operations instead of targeting consumers directly.
Seki told Reuters that Foxconn should be part of a potential broader partnership with Honda Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>), Nissan, and Mitsubishi Motors (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTSUY#OTC">MTSUY</a>) and confirmed that Foxconn was finalizing a deal with Mitsubishi to supply it with EVs.
Foxconn was working with Mitsubishi, Seki said during Wednesday&#8217;s event.
President Donald Trump&#8217;s 25% auto tariff&nbsp;<a target="_blank" href="https://www.benzinga.com/news/25/03/44522387/japanese-automakers-face-29-billion-tariff-hit-nissan-mazda-subaru-most-at-risk-says-analyst" rel="noreferrer noopener">threatens to disrupt</a> the global automotive industry, with analysts warning of sharp price increases and declining sales.
Goldman Sachs&nbsp;expected imported&nbsp;vehicle prices to surge by $5,000 to $15,000, while even U.S.-built cars could see cost hikes of $3,000 to $8,000 due to foreign-made parts. According to analyst Akira Kishimoto, Japanese automakers could face a potential hit of 4.46 trillion yen (about $29.44 billion).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/04/44668137/nio-power-in-deal-talks-with-tesla-battery-supplier-catl" target="_blank" rel="noreferrer noopener">Nio Power In Deal Talks With Tesla Battery Supplier CATL</a></li>
</ul>
Image: Shutterstock

Asia

Global

Tech

Media

AAPL

HNHAY

MTSUY

NSANF

NSANY

Foxconn Eyes Nissan, Mitsubishi In Japan EV Push To Counter China's Growing Auto Threat

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and maintains $42 price target.

RCKT

Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $42 Price Target

Needham analyst Mike Matson reiterates Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Hold to Hold.

INGN

Needham Reiterates Hold on Inogento Hold

Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) will release its fourth-quarter earnings results after the <a href="https://www.benzinga.com/quote/STZ/earnings">closing bell on Wednesday, April 9.</a>
Analysts expect the company to report quarterly earnings at $2.28 per share, up from $2.26 per share in the year-ago period. Constellation Brands projects to report quarterly revenue at $2.13 billion, compared to $2.14 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 3, Roth MKM analyst Bill Kirk maintained Constellation Brands with a Buy rating and lowered the price target from $284 to $256.
With the recent buzz around the company, some investors may be eyeing potential gains from its dividends, too. As of now, Constellation offers an annual dividend yield of 2.36%, which is a quarterly dividend of $1.01 per share ($4.04 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $253,876 or around 1,485 shares. For a more modest $100 per month or $1,200 per year, you would need $50,775 or around 297 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.04 in this case). So, $6,000 / $4.04 = 1,485 ($500 per month), and $1,200 / $4.04 = 297 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
STZ Price Action: Shares of Constellation Brands fell 0.9% to close at $170.96 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Constellation Brands Stock Ahead Of Q4 Earnings

Loop Capital analyst Garik Shmois initiates coverage on CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) with a Buy rating and announces Price Target of $114.

Initiation

Loop Capital Initiates Coverage On CRH with Buy Rating, Announces Price Target of $114

Collaboration to Deliver Agile, High-Performance Satellite Platforms for Commercial, Defense, and Government Customers Worldwide.
Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) (the "Company" or "Sidus"), an innovative, agile space mission enabler, today announced the signing of a Memorandum of Understanding (MOU) with Berlin-based <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.reflexaerospace.com%2F&amp;esheet=54235839&amp;newsitemid=20250409176057&amp;lan=en-US&amp;anchor=Reflex+Aerospace+GmbH&amp;index=1&amp;md5=afba4e503a4e3133f85e34f6a13e5503">Reflex Aerospace GmbH</a>, a cutting-edge European designer and manufacturer of high-performance, tailor-made satellites. The agreement was officially signed during the Space Foundation's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.spacesymposium.org%2F%3Fhsa_acc%3D2708741139%26hsa_cam%3D21151499714%26hsa_grp%26hsa_ad%26hsa_src%3Dx%26hsa_tgt%26hsa_kw%26hsa_mt%26hsa_net%3Dadwords%26hsa_ver%3D3%26gad_source%3D1%26gclid%3DCjwKCAjwktO_BhBrEiwAV70jXjhoRCJMelc5pH70ViS12WtQHk2POOpBfiindDSzay0m3mryFTX-JxoCRGUQAvD_BwE%26utm_term%3D%26utm_campaign%3DTSF%2B-%2BPmax%2B-%2BSymposium%2B-%2BLivestream%26utm_source%3Dadwords%26utm_medium%3Dppc&amp;esheet=54235839&amp;newsitemid=20250409176057&amp;lan=en-US&amp;anchor=40th+Space+Symposium&amp;index=2&amp;md5=52e9800fa4779750f799c402c8c0d660">40th Space Symposium</a> in Colorado Springs, CO, formalizing a partnership that began with a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.sidusspace.com%2Fnews-events%2Fpress-releases%2Fdetail%2F211%2Fsidus-space-and-reflex-aerospace-sign-letter-of-intent-at&amp;esheet=54235839&amp;newsitemid=20250409176057&amp;lan=en-US&amp;anchor=Letter+of+Intent&amp;index=3&amp;md5=bcfcafd2b86cb3dfc69f99894ffc89d9">Letter of Intent</a> at the Space Tech Expo Europe in November 2024. The agreement formally establishes the framework to form a U.S.-based Joint Venture focused on delivering flexible, cost-effective, and high-performance solutions to meet diverse customer needs while strengthening their presence in global markets.
Under the agreement, Sidus and Reflex will jointly develop and manufacture integrated satellite platforms leveraging Sidus' mission operations, technology integration and advanced manufacturing expertise alongside Reflex's rapid satellite development capabilities and high-performance components. The collaboration will target U.S. and European markets across defense, commercial, and government sectors, with both companies contributing to production, business development, and market distribution.

SIDU

Sidus Space And Reflex Aerospace Sign MOU To Establish U.S.-Based Joint Venture For Developing Agile Satellite Platforms Targeting Commercial, Defense, And Government Markets Worldwide, Strengthening Global Presence And Offering Flexible, Cost-Effective Solutions

The Simply Good Foods Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) shares are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Wednesday after the second-quarter fiscal 2025 earnings.
The company, led by CEO Geoff Tanner, reported<a href="https://www.benzinga.com/pressreleases/25/04/g44707558/the-simply-good-foods-company-reports-fiscal-second-quarter-2025-financial-results-and-reaffirms-f"> second-quarter FY25 sales growth of 15%</a> year-on-year to $359.65 million. It beat the analyst consensus estimate of $354.4 million.
OWYN net sales contributed $33.8 million, or 10.8%, to reported net sales growth, while organic net sales grew 4.4%, driven by Quest.
Gross profit was $130.1 million, an 11.4% increase, and gross margin contracted 120 basis points year over year to 36.2%.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
Operating expenses rose 9.6% to $75.4 million. Operating margin was 15.2%.
Adjusted EBITDA increased 17.6% Y/Y to $68 million.
Net income of $36.7 million improved by 10.9% from $35.9 million last year. Adjusted EPS of 46 cents beat the consensus estimate of 40 cents.
The company generated $63.3 million in operating cash flow during the six-month period and ended the second quarter with cash and equivalents totaling $103.6 million.
Outlook Reaffirmed: SMPL continues to expect FY25 net sales to grow 8.5% to 10.5%.
Adjusted EBITDA is expected to increase 4% to 6%.
Price Action: SMPL shares traded higher by 3.04% at $34.20 in premarket at last check Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44694350/intuitive-machines-taps-spacex-for-2027-lunar-mission-stock-gains">Intuitive Machines Taps SpaceX For 2027 Lunar Mission, Stock Gains</a></li>
</ul>
Image: Shutterstock

General

SMPL

Why Is Simply Good Foods Stock Gaining Today?

Successful robotic navigation was achieved in every case and&nbsp;met the primary endpoint of the study
LIBERTY&#xAE; showed a 92% reduction in radiation exposure with no adverse events reported
HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>), developer of the innovative LIBERTY&#xAE; Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study was performed at three leading medical centers in the U.S.; Memorial Sloan Kettering Cancer Center (New York, NY), Baptist Hospital of Miami (Miami, FL) and Brigham and Women's Hospital (Boston, MA). The late-breaking podium presentation was given by Francois Cornelis, M.D., PhD, Director of the Neuro Vascular Interventional Radiology Program at Memorial Sloan Kettering Cancer Center.
The data presented concluded that robotic endovascular procedures using LIBERTY&#xAE; are feasible and significantly minimize radiation exposure.
Significant Highlights of the ACCESS-PVI Study:
<ul>
<li>Successful robotic navigation was achieved in every case (N=20), yielding a success rate of 100%, meeting the primary endpoint of the study.</li>
<li>No Adverse Device Events (ADE=0%) were reported through the duration of follow-up.</li>
<li>Mean difference in radiation exposure between operator and control was (-)29.8 µS, resulting in a mean 92% relative reduction in radiation exposure.</li>
<li>Median robotic navigation time to target was 3 minutes.</li>
<li>Participating physicians reported LIBERTY&#xAE; performed as planned with a 100% satisfaction rate. &nbsp;</li>
</ul>
"The ACCESS-PVI data and the performance of the system throughout the study reflect the hard work that the team has put into LIBERTY&#xAE; over the past few years," commented Harel Gadot, Chairman, CEO and President. "We are extremely pleased with the results in all aspects. As we shift focus to building our commercial capabilities and preparing for launch, we are confident that LIBERTY&#xAE; will be well received in the market."
"We are very satisfied with the clinical data, as well as with the investigators' feedback in terms of the short learning curve and intuitive operation of the device," commented Dr. Juan Diaz-Cartelle, the Company's Chief Medical Officer. "We are looking forward to working with interventional physicians and staff upon FDA's clearance."

Biotech

MBOT

Microbot Medical Presented For Data For The First Time From Its ACCESS-PVI Trial At The Society Of Interventional Radiology Annual Meeting

Barclays analyst Brendan Lynch initiates coverage on Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Overweight rating and announces Price Target of $59.

LINE

Barclays Initiates Coverage On Lineage with Overweight Rating, Announces Price Target of $59

As the trusted network for AI, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4401708-1&amp;h=3920971206&amp;u=https%3A%2F%2Fnews.lumen.com%2Fhome&amp;a=Lumen+Technologies">Lumen Technologies</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) today announced at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4401708-1&amp;h=3310601013&amp;u=https%3A%2F%2Fcloud.withgoogle.com%2Fnext%2F25%3Futm_source%3Dcgc-site%26utm_medium%3Det%26utm_campaign%3DFY25-Q2-global-EXP106-physicalevent-er-next25-mc%26utm_content%3Dcgc-hp-event-card-save-the-date%26utm_term%3D-%26_gl%3D1%252a13d0gkd%252a_ga%252aMTYzMTk3NzQ2Mi4xNzQzNzI3OTg4%252a_ga_WH2QY8WWF5%252aMTc0Mzc5MTc2NC4yLjEuMTc0Mzc5MTg5Mi42MC4wLjA.&amp;a=Next+25">Next 25</a> that it is partnering with Google Cloud to deliver advanced cloud and network solutions that meet the rising demands of enterprise customers—particularly amid the rapid growth of AI workloads across industries.
The partnership centers on three key initiatives that will deliver the scalable, secure, and high-performance connectivity enterprises need to power their AI-driven transformation:&nbsp;
<ul>
<li>Integrating Google's new&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4401708-1&amp;h=726974439&amp;u=https%3A%2F%2Fcloud.google.com%2Fblog%2Fproducts%2Fnetworking%2Fconnect-globally-with-cloud-wan-for-the-ai-era&amp;a=Cloud+WAN">Cloud WAN</a> with Lumen connectivity services
<ul>
<li>This will modernize Lumen's Network-as-a-Service offerings so Lumen-managed SD-WAN and security services can be hosted in Google Cloud regions.</li>
</ul>
</li>
<li>In partnership with Google Cloud, Lumen is enabling direct 400 Gbps direct fiber connections from Google Cloud regions directly to customer locations
<ul>
<li>This will extend Lumen's connectivity to over 50,000 Lumen locations to Google Cloud, allowing Lumen to deliver substantial network capacity.</li>
</ul>
</li>
<li>Lumen will connect its encrypted network to&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4401708-1&amp;h=3543124307&amp;u=https%3A%2F%2Fcloud.google.com%2Fdistributed-cloud-air-gapped%3Fhl%3Den&amp;a=Google+Distributed+Cloud+air-gapped">Google Distributed Cloud air-gapped</a> deployments
<ul>
<li>This initiative provides Lumen's highly secure WAN network solutions for Google Distributed Cloud and is designed to address threats faced by large enterprises, financial services and public sectors.</li>
</ul>
</li>
</ul>

LUMN

Lumen Partners With Google Cloud To Deliver Next-Generation Network Infrastructure

<a href="https://www.globenewswire.com/Tracker?data=LbsLNQUR_FwciBNuifC_0n6Z0EgAy_1YP4OGCzULTZ0_evHdp0Beh4Ulq4xsSH4MTEmX6JBFSn4nihc3HhkN70b2Gif0bMsK1UyRnOqIkLw=">Navitas Semiconductor</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>), the only pure-play, next-generation power semiconductor company and industry leader in gallium nitride (GaN) power ICs and silicon carbide (SiC) technology, has announced a new strategic partnership with GigaDevice, a world-leader in microcontrollers (MCUs) and flash memory, to create a joint-lab for integrating and tailoring Navitas' GaNFast&#x2122; ICs &amp; GigaDevice's Microcontrollers, targeting AI data centers, EVs, Solar, and Energy Saving Systems.
As GaN &amp; SiC power technologies transition power conversion to faster, lighter, and more compact solutions, such as single-stage BDS converters, MCUs need to be optimized to maximize these extremely fast switching characteristics, such as high processing speeds and fast I/O capabilities.&nbsp;A co-developed solution of Navitas' power and GigaDevice's control will further accelerate the adoption of GaN &amp; SiC into higher-power markets.
The joint R&amp;D laboratory will integrate both company's technical product and system-level application expertise to drive innovative advancements in intelligent and efficient power management solutions. Integrating Navitas' next-generation, clean-energy, GaNFast&#x2122; technology with GigaDevice's advanced high-performance MCU products will enable a new level of integration, performance, and high-power-density digital-power solutions.

NVTS

Navitas Semiconductor Forms Strategic Partnership With GigaDevice To Create Joint Lab For Integrating GaNFast Power ICs With GigaDevice's Microcontrollers, Targeting AI Data Centers, EVs, Solar, And Energy Saving Systems For Advanced Power Management Solutions

LMNR

Limoneira Receives $10M As Its Share Of A $20M Cash Distribution From Its 50%/50% Real Estate Development JV

EDBL

Edible Garden Regains Compliance With Nasdaq Bid Price Requirement

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc analyst Paul Knight downgraded the rating for Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Overweight to Sector Weight. Bio-Techne shares closed at $48.81 on Tuesday. <a href="https://www.benzinga.com/quote/TECH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor downgraded Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Neutral. Rallybio shares closed at $0.25 on Tuesday. <a href="https://www.benzinga.com/quote/RLYB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Elizabeth Anderson downgraded the rating for Health Catalyst, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) from Outperform to In-Line and lowered the price target from $6 to $4. Health Catalyst shares closed at $3.82 on Tuesday. <a href="https://www.benzinga.com/quote/HCAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz downgraded Host Hotels &amp; Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) from Buy to Hold and cut the price target from $20 to $14. Host Hotels &amp; Resorts shares closed at $12.70 on Tuesday. <a href="https://www.benzinga.com/quote/HST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev downgraded the rating for PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) from Overweight to Neutral and lowered the price target from $210 to $160. PTC shares closed at $136.74 on Tuesday.  <a href="https://www.benzinga.com/quote/PTC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-1024x601.png" alt="" class="wp-image-863721" style="width:537px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09083138/image-52.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

HCAT

RLYB

TECH

This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108
No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date
Screening for Phase 1b UC cohort ongoing; On track to report topline data in the first half of 2025
Carlsbad, CA, April 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the completion of enrollment and dosing in all five Phase 1a SAD cohorts, all four MAD cohorts, and the food effects crossover in the Phase 1a portion of its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC).
Preliminary results show no SAEs and no TEAEs related to laboratory values or EKGs to date. The majority of observed TEAEs were considered mild, with only a single withdrawal in the highest 50 mg twice-daily dosage (BID) MAD cohort. Several of the MAD cohorts, ranging from 15 mg BID to 30 mg BID, were completed within the expected therapeutic dose range, again showing no SAEs or TEAEs related to laboratory values or EKGs. The 15 mg BID cohort was completed with no TEAEs, while the titrated 30 mg BID cohort was completed with a single mild TEAE. Given PALI-2108's high potency towards PDE4 B and D compared to other PDE4 inhibitors in preclinical studies, these results underscore its excellent tolerability at comparable dose levels. Screening and dosing of the Phase 1b UC patient cohort are ongoing, with one subject having completed this portion of the study. The Company is on track to report topline data from the Phase 1a portion of the study by the end of May 2025.
"We continue to make significant progress in our Phase 1a/b study of PALI-2108. With the completion of the Phase 1a portion and our ongoing efforts in screening, enrollment, and dosing within the Phase 1b cohort of UC patients, we remain on track to report topline data in the first half of 2025. Preliminary results from both our SAD and MAD cohorts support our confidence that we are dosing at the target therapeutic levels without encountering significant adverse events. This further strengthens our belief that PALI-2108 has the potential to offer a much-needed treatment option for patients with UC. We remain focused on the successful execution of the trial and look forward to sharing full topline data in the near future," said Dr. Mitch Jones, Chief Medical Officer of Palisade.

Comments

K92 Mining

K92 Mining (KNTNF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO